Sutro Biopharma, Inc. (STRO): Price and Financial Metrics

Sutro Biopharma, Inc. (STRO): $5.11

-0.11 (-2.11%)

POWR Rating

Component Grades














  • STRO scores best on the Growth dimension, with a Growth rank ahead of 88.87% of US stocks.
  • The strongest trend for STRO is in Quality, which has been heading up over the past 178 days.
  • STRO's current lowest rank is in the Momentum metric (where it is better than 9.24% of US stocks).

STRO Stock Summary

  • STRO's went public 4.48 years ago, making it older than only 21.13% of listed US stocks we're tracking.
  • Price to trailing twelve month operating cash flow for STRO is currently 51.44, higher than 91.94% of US stocks with positive operating cash flow.
  • Of note is the ratio of SUTRO BIOPHARMA INC's sales and general administrative expense to its total operating expenses; merely 15.61% of US stocks have a lower such ratio.
  • Stocks that are quantitatively similar to STRO, based on their financial statements, market capitalization, and price volatility, are BPMC, DTIL, MRKR, CDAK, and FUSN.
  • STRO's SEC filings can be seen here. And to visit SUTRO BIOPHARMA INC's official web site, go to

STRO Valuation Summary

  • In comparison to the median Healthcare stock, STRO's price/sales ratio is 126.32% higher, now standing at 4.3.
  • STRO's price/earnings ratio has moved up 14.7 over the prior 54 months.

Below are key valuation metrics over time for STRO.

Stock Date P/S P/B P/E EV/EBIT
STRO 2023-03-17 4.3 1.3 -2.4 -2.2
STRO 2023-03-16 4.3 1.3 -2.5 -2.2
STRO 2023-03-15 4.4 1.4 -2.5 -2.3
STRO 2023-03-14 4.5 1.4 -2.6 -2.4
STRO 2023-03-13 4.5 1.4 -2.5 -2.3
STRO 2023-03-10 4.2 1.3 -2.4 -2.2

STRO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • STRO has a Quality Grade of D, ranking ahead of 10.85% of graded US stocks.
  • STRO's asset turnover comes in at 0.194 -- ranking 205th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows STRO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.194 1 -0.301
2021-03-31 0.150 1 -0.169
2020-12-31 0.151 1 -0.155
2020-09-30 0.204 1 0.118
2020-06-30 0.212 1 -0.081
2020-03-31 0.246 1 -0.444

STRO Price Target

For more insight on analysts targets of STRO, see our STRO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.71 Average Broker Recommendation 1.38 (Strong Buy)

STRO Stock Price Chart Interactive Chart >

Price chart for STRO

STRO Price/Volume Stats

Current price $5.11 52-week high $9.59
Prev. close $5.22 52-week low $3.33
Day low $4.97 Volume 595,100
Day high $5.21 Avg. volume 525,485
50-day MA $6.53 Dividend yield N/A
200-day MA $6.27 Market Cap 293.70M

Sutro Biopharma, Inc. (STRO) Company Bio

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was founded in 2003 and is based in South San Francisco, California.

STRO Latest News Stream

Event/Time News Detail
Loading, please wait...

STRO Latest Social Stream

Loading social stream, please wait...

View Full STRO Social Stream

Latest STRO News From Around the Web

Below are the latest news stories about SUTRO BIOPHARMA INC that investors may wish to consider to help them evaluate STRO as an investment opportunity.

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on March 1, 2023, the Compensation Committee of Sutro’s Board of Directors (i) granted to Anne Borgman, M.D. 175,000 shares of Sutro Biopharma stock options and 150,000 restricted stock units (RSUs) of Sutro common stock in connection with her a

Yahoo | March 17, 2023

Sutro Biopharma, Inc. (NASDAQ:STRO) insider upped their holding by 4.3% earlier this year

Looking at Sutro Biopharma, Inc.'s ( NASDAQ:STRO ) insider transactions over the last year, we can see that insiders...

Yahoo | March 5, 2023

Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in an Ovarian Cancer panel discussion at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 9:10 a.m. ET / 6:10 a.m. PT in Boston, MA. The presentation will be acce

Yahoo | March 1, 2023

Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Anne Borgman, M.D., as Chief Medical Officer, effective February 28, 2023. Dr. Borgman brings over 20 years of oncology and hematology drug development experience to Sutro, including extensive regulatory experience in both the U.S.

Yahoo | February 28, 2023

Are Investors Undervaluing Sutro Biopharma, Inc. (NASDAQ:STRO) By 46%?

In this article we are going to estimate the intrinsic value of Sutro Biopharma, Inc. ( NASDAQ:STRO ) by estimating the...

Yahoo | January 27, 2023

Read More 'STRO' Stories Here

STRO Price Returns

1-mo -17.85%
3-mo -27.00%
6-mo -2.29%
1-year -35.88%
3-year -37.45%
5-year N/A
YTD -36.76%
2022 -45.70%
2021 -31.46%
2020 97.36%
2019 21.95%
2018 N/A

Continue Researching STRO

Here are a few links from around the web to help you further your research on Sutro Biopharma Inc's stock as an investment opportunity:

Sutro Biopharma Inc (STRO) Stock Price | Nasdaq
Sutro Biopharma Inc (STRO) Stock Quote, History and News - Yahoo Finance
Sutro Biopharma Inc (STRO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8217 seconds.